Home › NDC Lookup › Ingredients › Cetrorelix Acetate › 65219-0292-77
cetrorelix acetate Kit — NDC 65219-0292-77 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

cetrorelix acetate Kit — NDC 65219-292-77 (Billing 65219-0292-77)

by FRESENIUS KABI USA, LLC · 1 TRAY in 1 CARTON / 1 KIT in 1 TRAY * 1 mL in 1 VIAL, SINGLE-DOSE * 1 mL in 1 SYRINGE

This is a package of cetrorelix acetate Kit from FRESENIUS KABI USA, LLC, marketed since Jul 2024 and currently FDA-listed. It is this product's only package size.

NDC 65219-0292-77
🏷️ FDA NDC (as labeled) 65219-292-77 billing pads the product segment with a zero
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 65219-292-77 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
65219 labeler · 292 product · 77 package
Package marketed since
Jul 31, 2024
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 6521929277 7
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 65219-292-77
Product NDC 65219-292
11-digit billing NDC 65219029277
NCPDP billing unit EA — each (per item)
RxCUI 283402
Application # ANDA218150
SPL Set ID c9c50fcb-b28d-4085-9116-b38a21d31b99
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2024-07-31
Dosage form KIT
TE code (Orange Book) AP · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 047451
GCN 12526
HICL code 020305
Ingredient (HICL) Cetrorelix Acetate
HIC1 code P
Therapeutic class — broad (HIC1) Endocrine System
HIC2 code P1
Therapeutic class — intermediate (HIC2) Anteriorpituitary Hormones
HIC3 code P1N
Therapeutic class — specific (HIC3) Lhrh(Gnrh) Antagonist,Pituitary Suppressant Agents
AHFS code 68:18.04.00
AHFS class Antigonadtropins
FDB label name CETRORELIX ACETATE 0.25 MG VL
FDB brand name Cetrorelix Acetate
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 047451
  • GCN: 12526
  • HICL (First Databank): 020305
  • AHFS class code: 68:18.04.00
  • RxCUI (RxNorm): 283402
Why two NDCs? The FDA registers this code as 65219-292-77 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 65219-0292-77. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Gonadotropin Releasing Hormone Receptor Antagonist class.

Pharmacologic class Gonadotropin Releasing Hormone Receptor Antagonist
Drug family (ATC) Anti-gonadotropin-releasing hormones
How it works Gonadotropin Releasing Hormone Receptor Antagonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name CETRORELIX ACETATE 0.25 MG VL Ingredient Cetrorelix Acetate

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
65219-0292-77 You're viewing this Main listing 1 TRAY in 1 CARTON / 1 KIT in 1 TRAY * 1 mL in 1 VIAL, SINGLE-DOSE * 1 mL in 1 SYRINGE 2024-07-31 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Cetrotide 44087-1225-01 EMD 1 kit $306.057 AP FDA listed —
Cetrorelix 00480-5795-08 Teva 1 kit — — Discontinued —
Cetrorelix acetate 60505-6270-01 Apotex 1 kit — AP FDA listed —
cetrorelix acetatethis 65219-0292-77 FRESENIUS 1 kit — AP FDA listed —
Cetrorelix acetate 67184-0605-02 Qilu 1 kit — AP FDA listed —
cetrorelix acetate 68083-0600-01 Gland 1 kit — AP FDA listed —
Cetrorelix Acetate 71288-0558-90 Meitheal 1 kit — AP FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2024
On the market since
Jul 2024
📍
2026
Currently FDA-listed
2 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

A current SPL was checked, but it does not contain a structured or narrative inactive-ingredient list for this product. This does not mean the product has no inactive ingredients.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerFRESENIUS KABI USA, LLC
Application holderGLAND PHARMA LTD
FDA applicationANDA218150 (ANDA)
Labeler code65219
First marketedJul 2024
Product typeHuman Prescription Drug
Portfolio554 products on file

More NDCs from FRESENIUS KABI USA, LLC labeler code 65219

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🔄 Drug Interactions 🤰 Pregnancy 🧓 Geriatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description 💬 Information for Patients ⚠️ Precautions 🍼 Nursing Mothers 📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 📄 Patient Package Insert 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 22 words ▾

INDICATIONS AND USAGE Cetrorelix acetate for injection is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.

⏱️ Dosage and Administration ~2 min read ▾

DOSAGE AND ADMINISTRATION Ovarian stimulation therapy with gonadotropins (FSH, hMG) is started on cycle Day 2 or 3. The dose of gonadotropins should be adjusted according to individual response. Cetrorelix acetate for injection 0.25 mg may be administered subcutaneously once daily during the early- to mid-follicular phase.

Cetrorelix acetate for Injection 0.25 mg is administered on either stimulation day 5 (morning or evening) or day 6 (morning) and continued daily until the day of hCG administration. When assessment by ultrasound shows a sufficient number of follicles of adequate size, hCG is administered to induce ovulation and final maturation of the oocytes. No hCG should be administered if the ovaries show an excessive response to the treatment with gonadotropins to reduce the chance of developing ovarian hyperstimulation syndrome (OHSS).

Administration Cetrorelix acetate for Injection 0.25 mg can be administered by the patient herself after appropriate instructions by her doctor. Directions for using Cetrorelix Acetate for Injection 0.25 mg with the enclosed needles and pre-filled syringe: 1. Wash hands thoroughly with soap and water.

2. Flip off the plastic cover of the vial and wipe the aluminum ring and the rubber stopper with an alcohol swab. 3.

Twist the injection needle with the yellow mark (20 gauge) on the pre-filled syringe. 4. Push the needle through the center of the rubber stopper of the vial and slowly inject the solvent into the vial.

5. Leaving the syringe in the vial, gently swirl the vial until the solution is clear and without residues. Avoid forming bubbles.

6. Draw the total contents of the vial into the syringe. If necessary, invert the vial and pull back the needle as far as needed to withdraw the entire contents of the vial.

Discard unused portion. 7. Replace the needle with the yellow mark by the injection needle with the grey mark (27 gauge).

8. Invert the syringe and push the plunger until all air bubbles have been expelled. 9.

Choose an injection site in the lower abdominal area, preferably around, but staying at least one inch away from the navel. Choose a different injection site each day to minimize local irritation. Use a second alcohol swab to clean the skin at the injection site and allow alcohol to dry.

Gently pinch up the skin surrounding the site of injection. 10. Inject the prescribed dose as directed by your doctor, nurse or pharmacist.

11. Use the syringe and needles only once. Dispose of the syringe and needles properly after use.

If available, use a medical waste container for disposal.

⛔ Contraindications 44 words ▾

CONTRAINDICATIONS Cetrorelix acetate for injection is contraindicated under the following conditions: 1. Hypersensitivity to cetrorelix acetate, extrinsic peptide hormones or mannitol. 2. Known hypersensitivity to GnRH or any other GnRH analogs. 3. Known or suspected pregnancy, and lactation (see PRECAUTIONS). 4. Severe renal impairment.

⚠️ Warnings 32 words ▾

WARNINGS Cetrorelix acetate for injection should be prescribed by physicians who are experienced in fertility treatment. Before starting treatment with cetrorelix acetate for injection, pregnancy must be excluded (see CONTRAINDICATIONS and PRECAUTIONS).

🤒 Adverse Reactions ~2 min read ▾

ADVERSE REACTIONS The safety of cetrorelix acetate for injection in 949 patients undergoing controlled ovarian stimulation in clinical studies was evaluated. Women were between 19 and 40 years of age (mean: 32). 94.0% of them were Caucasian.

Cetrorelix acetate for injection was given in doses ranging from 0.1 mg to 5 mg as either a single or multiple dose. Table 3 shows systemic adverse events, reported in clinical studies without regard to causality, from the beginning of cetrorelix acetate for injection treatment until confirmation of pregnancy by ultrasound at an incidence ≥ 1% in cetrorelix acetate for injection treated subjects undergoing COS. Table 3: Adverse Events in ≥1% (WHO preferred term) Cetrorelix Acetate for Injection N=949 % (n) Ovarian Hyperstimulation Syndrome* 3.5 (33) Nausea 1.3 (12) Headache 1.1 (10) * Intensity moderate or severe, or WHO Grade II or III, respectively Local site reactions (e.g. redness, erythema, bruising, itching, swelling, and pruritus) were reported.

Usually, they were of a transient nature, mild intensity and short duration. During post-marketing surveillance, cases of mild to moderate Ovarian Hyperstimulation syndrome and cases of hypersensitivity reactions including anaphylactoid reactions have been reported. Two stillbirths were reported in Phase 3 studies of cetrorelix acetate for injection.

Congenital Anomalies Clinical follow-up studies of 316 newborns of women administered cetrorelix acetate for injection were reviewed. One infant of a set of twin neonates was found to have anencephaly at birth and died after four days. The other twin was normal.

Developmental findings from ongoing baby follow-up included a child with a ventricular septal defect and another child with bilateral congenital glaucoma. Four pregnancies that resulted in therapeutic abortion in Phase 2 and Phase 3 controlled ovarian stimulation studies had major anomalies (diaphragmatic hernia, trisomy 21, Klinefelter syndrome, polymalformation, and trisomy 18). In three of these four cases, intracytoplasmic sperm injection (ICSI) was the fertilization method employed; in the fourth case, in vitro fertilization (IVF) was the method employed.

The minor congenital anomalies reported include: supernumerary nipple, bilateral strabismus, imperforate hymen, congenital nevi, hemangiomata, and QT syndrome. The causal relationship between the reported anomalies and cetrorelix acetate for injection is unknown. Multiple factors, genetic and others (including, but not limited to ICSI, IVF, gonadotropins, and progesterone) make causal attribution difficult to study.

To report SUSPECTED ADVERSE REACTIONS contact Gland Pharma Limited at (609)-250‐7990 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

🔄 Drug Interactions 15 words ▾

Drug Interactions No formal drug interaction studies have been performed with cetrorelix acetate for injection.

🤰 Pregnancy 185 words ▾

Pregnancy (see CONTRAINDICATIONS) Cetrorelix acetate for injection is contraindicated in pregnant women. When administered to rats for the first seven days of pregnancy, cetrorelix acetate did not affect the development of the implanted conceptus at doses up to 38 mcg/kg (approximately 1 times the recommended human therapeutic dose based on body surface area). However, a dose of 139 mcg/kg (approximately 4 times the human dose) resulted in a resorption rate and a postimplantation loss of 100%.

When administered from day 6 to near term to pregnant rats and rabbits, very early resorptions and total implantation losses were seen in rats at doses from 4.6 mcg/kg (0.2 times the human dose) and in rabbits at doses from 6.8 mcg/kg (0.4 times the human dose). In animals that maintained their pregnancy, there was no increase in the incidence of fetal abnormalities. The fetal resorption observed in animals is a logical consequence of the alteration in hormonal levels effected by the antigonadotrophic properties of cetrorelix acetate for injection, which could result in fetal loss in humans as well.

Therefore, this drug should not be used in pregnant women.

🧓 Geriatric Use 18 words ▾

Geriatric Use Cetrorelix acetate for injection is not intended to be used in subjects aged 65 and over.

🆘 Overdosage 44 words ▾

OVERDOSAGE There have been no reports of overdosage with cetrorelix acetate for injection 0.25 mg or 3 mg in humans. Single doses up to 120 mg cetrorelix acetate for injection have been well tolerated in patients treated for other indications without signs of overdosage.

🧬 Clinical Pharmacology ~3 min read ▾

CLINICAL PHARMACOLOGY GnRH induces the production and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the gonadotrophic cells of the anterior pituitary. Due to a positive estradiol (E2) feedback at midcycle, GnRH liberation is enhanced resulting in an LH-surge. This LH-surge induces the ovulation of the dominant follicle, resumption of oocyte meiosis and subsequently luteinization as indicated by rising progesterone levels.

Cetrorelix acetate for injection competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner. The onset of LH suppression is approximately one hour with the 3 mg dose and two hours with the 0.25 mg dose. This suppression is maintained by continuous treatment and there is a more pronounced effect on LH than on FSH.

An initial release of endogenous gonadotropins has not been detected with cetrorelix acetate for injection, which is consistent with an antagonist effect. The effects of cetrorelix acetate for injection on LH and FSH are reversible after discontinuation of treatment. In women, cetrorelix acetate for injection delays the LH-surge, and consequently ovulation, in a dose-dependent fashion.

FSH levels are not affected at the doses used during controlled ovarian stimulation. Following a single 3 mg dose of cetrorelix acetate for injection, duration of action of at least 4 days has been established. A dose of cetrorelix acetate for injection 0.25 mg every 24 hours has been shown to maintain the effect.

Pharmacokinetics The pharmacokinetic parameters of single and multiple doses of cetrorelix acetate for injection in adult healthy female subjects are summarized in Table 1. Table 1: Pharmacokinetic parameters of Cetrorelix Acetate for Injection following 3 mg single or 0.25 mg single and multiple (daily for 14 days) subcutaneous (sc) administration. Single dose 3 mg Single dose 0.25 mg Multiple dose 0.25 mg No. of subjects 12 12 12 t max *[h] 1.5 (0.5-2) 1.0 (0.5-1.5) 1.0 (0.5-2) t 1/2 *[h] 62.8 (38.2-108) 5.0 (2.4-48.8) 20.6 (4.1-179.3) C max [ng/ml] 28.5 (22.5-36.2) 4.97 (4.17-5.92) 6.42 (5.18-7.96) AUC [ng∙h/ml] 536 (451-636) 31.4 (23.4-42.0) 44.5 (36.7-54.2) CL † [ml/min∙kg] 1.28 ‡ Vz † [l/kg] 1.16 ‡ tmax Time to reach observed maximum plasma concentration t 1/2 Elimination half-life C max Maximum plasma concentration; multiple dose C ss, max AUC Area under the curve; single dose AUC 0-inf , multiple dose AUC t CL Total plasma clearance Vz Volume of distribution Geometric mean (95% Cl In ), * median (min-max) † arithmetic mean, ‡ Based on iv administration (n=6, separate study 0013) Absorption Cetrorelix acetate for injection is rapidly absorbed following subcutaneous injection, maximal plasma concentrations being achieved approximately one to two hours after administration.

The mean absolute bioavailability of cetrorelix acetate for injection following subcutaneous administration to healthy female subjects is 85%. Distribution The volume of distribution of cetrorelix acetate for injection following a single intravenous dose of 3 mg is about 1 l/kg. In vitro protein binding to human plasma is 86%.

Cetrorelix acetate for injection concentrations in follicular fluid and plasma were similar on the day of oocyte pick-up in patients undergoing controlled ovarian stimulation. Following subcutaneous administration of cetrorelix acetate for injection 0.25 mg and 3 mg, plasma concentrations of cetrorelix were below or in the range of the lower limit of quantitation on the day of oocyte pick-up and embryo transfer. Metabolism After subcutaneous administration of 10 mg cetrorelix acetate for injection to females and males, cetrorelix acetate for injection and small amounts of (1-9), (1-7), (1-6), and (1-4) peptides were found in bile samples over 24 hours.

In in vitro studies, cetrorelix acetate for injection was stable against phase I- and phase II-metabolism. Cetrorelix acetate for injectio… [Excerpted — this section continues on DailyMed.]

📦 How Supplied / Storage and Handling 104 words ▾

HOW SUPPLIED Presentation Unit of Sale Description Cetrorelix Acetate for Injection Kit NDC 65219-292-77 Each packaged tray contains: One glass vial containing 0.26 – 0.27 mg cetrorelix acetate (corresponding to 0.25 mg cetrorelix) (NDC 65219-290-02) One pre-filled glass syringe with 1 mL of Sterile Water for Injection, USP (NDC 65219-286-01) One 20 gauge needle (yellow) and One 27 gauge need (grey) Storage Store Cetrorelix Acetate for Injection 0.25 mg refrigerated, 2-8°C (36-46°F). Store the packaged tray in the outer carton in order to protect from light.

Rx only Manufactured for: Lake Zurich, IL 60047 www.fresenius-kabi.com/us Made in India 451801 Revised: 04/2024 Fresnius Kabi Logo

📋 Description 119 words ▾

DESCRIPTION Cetrorelix acetate for injection is a synthetic decapeptide with gonadotropin-releasing hormone (GnRH) antagonistic activity. Cetrorelix acetate is an analog of native GnRH with substitutions of amino acids at positions 1, 2, 3, 6, and 10. The molecular formula is Acetyl-D-3-(2´-naphtyl)-alanine-D-4-chlorophenylalanine-D-3-(3´-pyridyl)-alanine -L-serine-L-tyrosine-D-citruline-L-leucine-L-arginine-L-proline-D-alanine-amide, and the molecular weight is 1431.06, calculated as the anhydrous free base.

The structural formula is as follows: Cetrorelix acetate (Ac-D-Nal1-D-Cpa2-D-Pal3-Ser4-Tyr5-D-Cit6-Leu7-Arg8-Pro9-D-Ala10-NH2) Cetrorelix Acetate for Injection 0.25 mg is a sterile lyophilized powder intended for subcutaneous injection after reconstitution with Sterile Water for Injection, USP, that comes supplied in a 1.0 mL pre-filled syringe. Each vial of cetrorelix acetate for injection 0.25 mg contains 0.26-0.27 mg cetrorelix acetate, equivalent to 0.25 mg cetrorelix, and 54.8 mg mannitol. cetrorelix-spl-structure

💬 Information for Patients 75 words ▾

Information for Patients Prior to therapy with cetrorelix acetate for injection, patients should be informed of the duration of treatment and monitoring procedures that will be required. The risk of possible adverse reactions should be discussed (see ADVERSE REACTIONS). Cetrorelix acetate for injection should not be prescribed if a patient is pregnant.

If cetrorelix acetate for injection is prescribed to patients for self-administration, information for proper use is given in the Patient Leaflet (see below).

⚠️ Precautions ~3 min read ▾

PRECAUTIONS General Cases of hypersensitivity reactions, including anaphylactoid reactions with the first dose, have been reported during post-marketing surveillance (see ADVERSE REACTIONS). A severe anaphylactic reaction associated with cough, rash, and hypotension, was observed in one patient after seven months of treatment with cetrorelix acetate for injection (10 mg/day) in a study for an indication unrelated to infertility. Special care should be taken in women with signs and symptoms of active allergic conditions or known history of allergic predisposition.

Treatment with cetrorelix acetate for injection is not advised in women with severe allergic conditions. Information for Patients Prior to therapy with cetrorelix acetate for injection, patients should be informed of the duration of treatment and monitoring procedures that will be required. The risk of possible adverse reactions should be discussed (see ADVERSE REACTIONS).

Cetrorelix acetate for injection should not be prescribed if a patient is pregnant. If cetrorelix acetate for injection is prescribed to patients for self-administration, information for proper use is given in the Patient Leaflet (see below). Laboratory Tests After the exclusion of preexisting conditions, enzyme elevations (ALT, AST, GGT, alkaline phosphatase) were found in 1-2% of patients receiving cetrorelix acetate for injection during controlled ovarian stimulation.

The elevations ranged up to three times the upper limit of normal. The clinical significance of these findings was not determined. During stimulation with human menopausal gonadotropin, cetrorelix acetate for injection had no notable effects on hormone levels aside from inhibition of LH surges.

Drug Interactions No formal drug interaction studies have been performed with cetrorelix acetate for injection. Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term carcinogenicity studies in animals have not been performed with cetrorelix acetate. Cetrorelix acetate was not genotoxic in vitro (Ames test, HPRT test, chromosome aberration test) or in vivo (chromosome aberration test, mouse micronucleus test).

Cetrorelix acetate induced polyploidy in CHL-Chinese hamster lung fibroblasts, but not in V79-Chinese hamster lung fibroblasts, cultured peripheral human lymphocytes or in an in vitro micronucleus test in the CHL-cell line. Treatment with 0.46 mg/kg cetrorelix acetate for 4 weeks resulted in complete infertility in female rats which was reversed 8 weeks after cessation of treatment. Pregnancy (see CONTRAINDICATIONS) Cetrorelix acetate for injection is contraindicated in pregnant women.

When administered to rats for the first seven days of pregnancy, cetrorelix acetate did not affect the development of the implanted conceptus at doses up to 38 mcg/kg (approximately 1 times the recommended human therapeutic dose based on body surface area). However, a dose of 139 mcg/kg (approximately 4 times the human dose) resulted in a resorption rate and a postimplantation loss of 100%. When administered from day 6 to near term to pregnant rats and rabbits, very early resorptions and total implantation losses were seen in rats at doses from 4.6 mcg/kg (0.2 times the human dose) and in rabbits at doses from 6.8 mcg/kg (0.4 times the human dose).

In animals that maintained their pregnancy, there was no increase in the incidence of fetal abnormalities. The fetal resorption observed in animals is a logical consequence of the alteration in hormonal levels effected by the antigonadotrophic properties of cetrorelix acetate for injection, which could result in fetal loss in humans as well. Therefore, this drug should not be used in pregnant women.

Nursing Mothers It is not known whether cetrorelix acetate for injection is excreted in human milk. Because many drugs are excreted in human milk, and because the effects of cetrorelix acetate for injection on lactation and/or the breast-fed child have not been determined, cetrorelix acetate for injection sh… [Excerpted — this section continues on DailyMed.]

🍼 Nursing Mothers 54 words ▾

Nursing Mothers It is not known whether cetrorelix acetate for injection is excreted in human milk. Because many drugs are excreted in human milk, and because the effects of cetrorelix acetate for injection on lactation and/or the breast-fed child have not been determined, cetrorelix acetate for injection should not be used by nursing mothers.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 96 words ▾

Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term carcinogenicity studies in animals have not been performed with cetrorelix acetate. Cetrorelix acetate was not genotoxic in vitro (Ames test, HPRT test, chromosome aberration test) or in vivo (chromosome aberration test, mouse micronucleus test). Cetrorelix acetate induced polyploidy in CHL-Chinese hamster lung fibroblasts, but not in V79-Chinese hamster lung fibroblasts, cultured peripheral human lymphocytes or in an in vitro micronucleus test in the CHL-cell line.

Treatment with 0.46 mg/kg cetrorelix acetate for 4 weeks resulted in complete infertility in female rats which was reversed 8 weeks after cessation of treatment.

📄 Patient Package Insert ~3 min read ▾

Patient Leaflet Cetrorelix Acetate for Injection 0.25 mg Active ingredient: cetrorelix acetate Summary Cetrorelix Acetate for Injection blocks the effects of a natural hormone, called gonadotropin-releasing hormone (GnRH). GnRH controls the secretion of another hormone, called luteinizing hormone (LH), which induces ovulation during the menstrual cycle. During hormone treatment for ovarian stimulation, premature ovulation may lead to eggs that are not suitable for fertilization.

Cetrorelix Acetate for Injection blocks such undesirable premature ovulation. Uses Cetrorelix Acetate for Injection is used to prevent premature ovulation during controlled ovarian stimulation. General Cautions Do not use Cetrorelix Acetate for Injection if you • have kidney disease • are allergic to cetrorelix acetate, mannitol or exogenous peptide hormones (medicines similar to cetrorelix acetate for injection) or • are pregnant, or think that you might be pregnant, or if you are breast-feeding.

Consult your doctor before taking Cetrorelix Acetate for Injection if you have had severe allergic reactions. Proper Use Ovarian stimulation therapy is started on cycle Day 2 or 3. Cetrorelix Acetate for Injection 0.25 mg is injected under the skin once daily, as directed by your physician.

When an ultrasound examination shows that you are ready, another drug (hCG) is injected to induce ovulation. How should you use Cetrorelix Acetate for Injection? You may self-inject cetrorelix acetate for injection after special instruction from your doctor.

To fully benefit from cetrorelix acetate for injection, please read carefully and follow the instructions given below, unless your doctor advises you otherwise. Cetrorelix acetate for injection is for injection under the skin of the lower abdominal area, preferably around, but staying at least one inch away from the belly button. Choose a different injection site each day to minimize local irritation.

Dissolve cetrorelix acetate for injection, powder only with the water contained in the pre-filled syringe. Do not use a cetrorelix acetate for injection, solution if it contains particles or if it is not clear. Before you inject cetrorelix acetate for injection, yourself, please read the following instructions carefully: Directions for using Cetrorelix Acetate for Injection 0.25 mg with the enclosed needles and pre-filled syringe: 1.

Wash your hands thoroughly with soap and water. 2. On a clean flat surface, lay out everything you need (one vial of powder, one pre-filled syringe, one injection needle with a yellow mark, and one injection needle with a grey mark).

3. Flip off the plastic cover of the vial. Wipe the aluminum ring and the rubber stopper with an alcohol swab.

4. Take the injection needle with the yellow mark and remove the wrapping. Take the pre-filled syringe and remove the cover.

Twist the needle on the syringe and remove the cover of the needle. 5. Push the needle through the center of the rubber stopper of the vial.

Inject the water into the vial by slowly pushing down on the plunger of the syringe. 6. Leave the syringe in the vial.

While carefully holding the syringe and vial, swirl gently to mix the powder and water together. When it is mixed, it will look clear and have no particles in it. Do not shake or you will create bubbles in your medicine.

7. Draw the total contents of the vial into the syringe. If liquid is left in the vial, invert the vial, pull back the needle until the opening of the needle is just inside the stopper.

If you look from the side through the gap in the stopper, you can control the movement of the needle and the liquid. It is important to withdraw the entire contents of the vial. Discard unused portion.

8. Detach the syringe from the needle and lay down the syringe. Take the injection needle with the grey mark and remove its wrapping.

Twist the needle on the syringe and remove the cover of the needle. 9. Invert the syringe and push the plunger until all air bubbles have been pus… [Excerpted — this section continues on DailyMed.]

📄 Package Label / Principal Display Panel ~1 min read ▾

PACKAGE LABEL - PRINCIPAL DISPLAY – Cetrorelix Acetate Single-Dose Vial Label NDC 65219- 290 -02 Rx only Cetrorelix Acetate for Injection 0.25 mg/vial FOR SUBCUTANEOUS USE ONLY. STERILE Store vial protected from light. Store refrigerated, 2-8°C (36-46°F) Single-Dose Vial PACKAGE LABEL - PRINCIPAL DISPLAY – Cetrorelix Acetate Single-Dose Vial Label

PDP INFO – Cetrorelix Acetate for Injection 286701 PFS PACKAGE LABEL - PRINCIPAL DISPLAY – Cetrorelix Acetate 1 mL Prefilled Syringe Label NDC 65219- 286 -01 Rx only 1 mL Prefilled Sterile Water for Injection, USP PDP INFO – Cetrorelix Acetate for Injection 286701 PFS

PACKAGE LABEL - PRINCIPAL DISPLAY – Cetrorelix Acetate Blister Foil Label NDC 65219- 292 -77 Rx only Cetrorelix Acetate for Injection 0.25 mg/vial Contains: One single-dose vial with lyophilized powder for reconstitution, one pre-filled syringe with diluent, one 20-gauge needle and one 27-gauge needle. Store the packaged tray in the outer carton. Store refrigerated, 2-8°C (36-46°F) FOR SUBCUTANEOUS USE ONLY.

STERILE PACKAGE LABEL - PRINCIPAL DISPLAY – Cetrorelix Acetate Blister Foil Label

PACKAGE LABEL - PRINCIPAL DISPLAY - Cetrorelix Acetate Kit Carton Label NDC 65219- 292 -77 Rx only Cetrorelix Acetate for Injection 0.25 mg/vial FOR SUBCUTANEOUS USE ONLY. STERILE Store refrigerated, 2-8°C (36-46°F) One carton contains one packaged tray which contains: 1 single-dose vial with lyophilized powder for reconstitution 1 pre-filled syringe with diluent 1 20-gauge needle 1 27-gauge needle PACKAGE LABEL - PRINCIPAL DISPLAY - Cetrorelix Acetate Kit Carton Labe

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Cetrorelix Acetate — the ingredient across all brands.

Top reported reactions

Ovarian Hyperstimulation Syndrome135
Premature Ovulation40
Abortion Spontaneous39
Ascites28
Abdominal Distension27
Abdominal Pain26
Nausea24

Age at onset

Neonate8
Adolescent5
Adult100
Elderly1

Reporter sex

617 reports

Serious outcomes

Life-threatening24
Death7
Disabling6
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 94 23
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

Finished prescription product Kit / multi-component package

Kit / multi-component package

This NDC identifies a kit — a package containing more than one component. Structured data (pricing, ingredients, equivalents) is often reported per component rather than for the kit NDC itself, which can make this page look thinner than the components' own pages.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by FRESENIUS KABI USA, LLC. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
FRESENIUS KABI USA, LLC is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 65219-0289-65 · Fresenius 65219-0293-01 · Fresenius →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.